FDA warns telehealth seller Mint Med that its website labels falsely suggest it compounds the semaglutide and tirzepatide drugs it sells.
What happened
FDA reviewed Mint Med's website, https://mintmed.com, in May 2026 and found it offers compounded semaglutide and tirzepatide drug products. The labels pictured on the site show "Mint Med" on the product label, which suggests Mint Med is the compounder of those drugs when it is not. FDA calls those representations false or misleading, which makes the products misbranded.
What FDA found
The website shows compounded semaglutide and tirzepatide products with "Mint Med" on the label, which falsely suggests Mint Med made the drugs.
FD&C Act § 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)Advertising or promoting a compounded drug with false or misleading claims misbrands the drug.
FD&C Act § 502(bb) [21 U.S.C. § 352(bb)]Selling these misbranded drugs across state lines is a prohibited act.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]Compounded drugs must meet the conditions of section 503A or 503B to be exempt from the new drug approval requirements.
FD&C Act §§ 503A and 503B [21 U.S.C. §§ 353a and 353b]
What FDA wants
FDA asks the company to send a written response to its Office of Compounding Quality and Compliance within 15 business days, naming the entities that make the drugs, providing sample labeling, and correcting or removing the misleading website claims.
Who should pay attention
- telehealth platforms selling compounded semaglutide and tirzepatide
- compounding pharmacies whose products are resold under another company's name
- marketers that put their own name on drug labels they do not manufacture
This is a summary. Read the original letter on fda.gov.